Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11489927 | 0.88 | CYP4F2 (0.48) | FFAR1TTRSLC6A4ARL3MBTL1 | |
| SCHEMBL14662604 | 0.84 | EPAS1 (0.44) | FFAR1TTRARKIF11 | |
| SCHEMBL875557 | 0.84 | EPAS1 (0.52) | FFAR1TTRARL3MBTL1MAPT | |
| SCHEMBL14656214 | 0.84 | TTR (0.51) | TTRRAB9AS1PR1S1PR3 | |
| SCHEMBL21158175 | 0.83 | TTR (0.40) | FFAR1TTRARL3MBTL1LMNA | |
| SCHEMBL875984 | 0.82 | AR (0.53) | FFAR1TTRSLC6A4ARHTR2A | |
| SCHEMBL14661984 | 0.82 | TLR8 (0.40) | FFAR1TTRARKIF11 | |
| SCHEMBL14656435 | 0.81 | THRB (0.41) | FFAR1SLC6A4MAPK14THRBMAOB | |
| SCHEMBL19154082 | 0.81 | ROCK2 (0.41) | FFAR1TTRARMAOBS1PR1 | |
| SCHEMBL13218236 | 0.81 | TTR (0.70) | TTRSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4056571-A1 | TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| EP-2948456-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | PLA2G4A, PLA2G7, PLA2G6 | FFAR1 883/4885TTR 2219/4885SLC6A4 3696/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | FFAR1 226/4885TTR 2161/4885SLC6A4 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.